Becton, Dickinson and Company (NYSE:BDX) Receives Consensus Recommendation of “Buy” from Brokerages

Becton, Dickinson and Company (NYSE:BDX) has been assigned an average rating of “Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $282.63.

A number of equities analysts have commented on BDX shares. Raymond James reduced their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of large investors have recently bought and sold shares of BDX. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company in the third quarter valued at approximately $26,000. Sound Income Strategies LLC boosted its position in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in Becton, Dickinson and Company in the 2nd quarter worth approximately $45,000. Abound Wealth Management boosted its position in Becton, Dickinson and Company by 96.0% in the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC boosted its position in Becton, Dickinson and Company by 1,233.3% in the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 185 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $238.62 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The business has a 50-day moving average price of $237.33 and a 200 day moving average price of $235.16. The company has a market capitalization of $68.96 billion, a P/E ratio of 52.56, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $262.23.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.96 earnings per share. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.